BR0013180A - Oligonucleotìdeos para inibição da expressão de eg5 humano - Google Patents

Oligonucleotìdeos para inibição da expressão de eg5 humano

Info

Publication number
BR0013180A
BR0013180A BR0013180-6A BR0013180A BR0013180A BR 0013180 A BR0013180 A BR 0013180A BR 0013180 A BR0013180 A BR 0013180A BR 0013180 A BR0013180 A BR 0013180A
Authority
BR
Brazil
Prior art keywords
expression
oligonucleotides
inhibiting human
human
oligonucleotide
Prior art date
Application number
BR0013180-6A
Other languages
English (en)
Inventor
Eugen Uhlmann
Beate Greiner
Eberhard Unger
Gislinde Gothe
Marc Schwerdel
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of BR0013180A publication Critical patent/BR0013180A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Patente de Invenção: "OLIGONUCLEOTìDEOS PARA INIBIçãO DA EXPRESSãO DE eg5 HUMANO". A invenção refere-se a um oligonucleotídeo ou a um de seus derivados, caracterizado pelo fato de que apresenta uma seq³ência, que corresponde a uma determinada parte de uma seq³ência de ácido nucléico que codifica eg5 humano ou uma forma mutante do mesmo; além disso, a invenção refere-se a um processo para produção do oligonucleotídeo e uso do mesmo.
BR0013180-6A 1999-07-28 2000-07-21 Oligonucleotìdeos para inibição da expressão de eg5 humano BR0013180A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19935303A DE19935303A1 (de) 1999-07-28 1999-07-28 Oligonukleotide zur Inhibierung der Expression von humanem eg5
PCT/EP2000/007345 WO2001007602A2 (de) 1999-07-28 2000-07-21 Oligonukleotide zur inhibierung der expression von humanem eg5

Publications (1)

Publication Number Publication Date
BR0013180A true BR0013180A (pt) 2002-04-09

Family

ID=7916259

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0013180-6A BR0013180A (pt) 1999-07-28 2000-07-21 Oligonucleotìdeos para inibição da expressão de eg5 humano

Country Status (26)

Country Link
US (1) US6472521B1 (pt)
EP (1) EP1204742A2 (pt)
JP (1) JP2003505080A (pt)
KR (1) KR20020033744A (pt)
CN (1) CN1165617C (pt)
AR (1) AR024953A1 (pt)
AU (1) AU6568200A (pt)
BR (1) BR0013180A (pt)
CA (1) CA2380192A1 (pt)
CZ (1) CZ2002324A3 (pt)
DE (1) DE19935303A1 (pt)
EE (1) EE200200044A (pt)
HK (1) HK1048337B (pt)
HR (1) HRP20020075A2 (pt)
HU (1) HUP0202794A3 (pt)
IL (1) IL147541A0 (pt)
MX (1) MXPA02000817A (pt)
NO (1) NO20020365L (pt)
NZ (1) NZ516839A (pt)
PL (1) PL353733A1 (pt)
RU (1) RU2249458C2 (pt)
SK (1) SK1162002A3 (pt)
TR (1) TR200200201T2 (pt)
WO (1) WO2001007602A2 (pt)
YU (1) YU91901A (pt)
ZA (1) ZA200200655B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617115B1 (en) * 1999-10-27 2003-09-09 Cytokinetics, Inc. Methods of screening for modulators of cell proliferation
US6440686B1 (en) 2000-06-15 2002-08-27 Cytokinetics, Inc. Methods for screening and therapeutic applications of kinesin modulators
US6809102B2 (en) 2001-03-29 2004-10-26 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US20040009156A1 (en) * 2001-10-12 2004-01-15 Christoph Reinhard Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer
US7199107B2 (en) * 2002-05-23 2007-04-03 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
US7163927B2 (en) * 2002-05-23 2007-01-16 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
WO2004074301A2 (en) * 2003-02-14 2004-09-02 Smithkline Beecham Corporation Differentially expressed nucleic acids that correlate with ksp expression
US7662581B1 (en) 2003-12-18 2010-02-16 Novartis Vaccines And Diagnostics, Inc. Eg5 co-crystals
EP1737979B9 (en) * 2004-03-23 2011-09-21 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancer
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
NZ571568A (en) * 2006-03-31 2010-11-26 Alnylam Pharmaceuticals Inc Double-stranded RNA molecule compositions and methods for inhibiting expression of Eg5 gene
RU2568579C2 (ru) * 2006-05-26 2015-11-20 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" Введение противосвертывающей системы reg1
RU2464030C2 (ru) * 2006-05-26 2012-10-20 Регадо Байосайенсиз, Инк. Введение противосвертывающей системы reg1
DK2207787T3 (en) * 2007-11-06 2015-02-09 Adiutide Pharmaceuticals Gmbh Immunostimulatory oligoribonukleotidanaloger containing modified oligofosfatenheder
DE102010007562A1 (de) 2010-02-10 2011-08-11 sterna biologicals GmbH & Co KG, 35043 Dermatologische, pharmazeutische Zusammensetzung geeignet für Oligonukleotide
LT2750768T (lt) 2011-08-30 2019-02-11 Astex Pharmaceuticals, Inc. Decitabino darinio kompozicijos
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
RU2686080C2 (ru) * 2013-05-01 2019-04-24 Ионис Фармасьютикалз, Инк. Композиции и способы
AU2014312196C1 (en) * 2013-08-28 2019-12-19 Ionis Pharmaceuticals, Inc. Modulation of prekallikrein (PKK) expression
MY192689A (en) * 2013-10-11 2022-09-01 Ionis Pharmaceuticals Inc Compositions for modulating c9orf72 expression
RS59182B1 (sr) * 2014-05-01 2019-10-31 Ionis Pharmaceuticals Inc Kompozicije i postupci za modulaciju ekspresije faktora b komplementa
AU2016287585B2 (en) 2015-07-02 2020-12-17 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
MX2020001233A (es) 2017-08-03 2020-07-20 Otsuka Pharma Co Ltd Compuesto farmaceutico y metodos de purificacion del mismo.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0171066A3 (de) 1984-08-09 1989-02-01 Siemens Aktiengesellschaft Verfahren und Schaltungsanordnung zum Adressieren von Signalabgabe-/Signalaufnahmeeinrichtungen von einer zentralen Verarbeitungseinrichtung her
DE59108644D1 (de) 1990-07-02 1997-05-07 Hoechst Ag Oligonucleotid-analoge mit terminalen 3'-3'-bzw. 5'-5'-Internucleotidverknüpfungen
US6033909A (en) 1992-01-22 2000-03-07 Hoechst Aktiengesellschaft Oligonucleotide analogs, their preparation and use
KR930016437A (ko) 1992-01-22 1993-08-26 귀틀라인, 슈미트 올리고뉴클레오티드 유사체, 이의 제조방법 및 용도
DE59306170D1 (de) 1992-09-24 1997-05-22 Hoechst Ag Oligoribonucleotid- und Ribozym-Analoga mit terminalen 3'-3'-bzw.5'-5'-Verknüpfungen
GB9311113D0 (en) * 1993-05-28 1993-07-14 Medical Res Council Probes
DE4321946A1 (de) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
DE4338704A1 (de) 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
DE4408528A1 (de) 1994-03-14 1995-09-28 Hoechst Ag Peptid-Oligonucleotid-Derivate, deren Herstellung und Verwendung
DE4415370A1 (de) 1994-05-02 1995-11-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
DE4438918A1 (de) 1994-11-04 1996-05-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
DE19502912A1 (de) 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
ES2165446T3 (es) 1995-03-13 2002-03-16 Aventis Pharma Gmbh Fosfonomonoester-acidos nucleicos, procedimiento para su preparacion y su utilizacion.
US6309821B1 (en) * 1996-05-16 2001-10-30 Incyte Genomics, Inc. DNA encoding a PAC10 human homolog
AU8656098A (en) * 1997-07-23 1999-02-16 Brigham And Women's Hospital Lens epithelial cell derived growth factor
WO1999038972A2 (en) * 1998-01-28 1999-08-05 Chiron Corporation Human genes and gene expression products ii

Also Published As

Publication number Publication date
IL147541A0 (en) 2002-08-14
WO2001007602A3 (de) 2001-05-17
YU91901A (sh) 2003-02-28
CZ2002324A3 (cs) 2002-05-15
EE200200044A (et) 2003-06-16
RU2249458C2 (ru) 2005-04-10
NO20020365L (no) 2002-03-25
CN1367828A (zh) 2002-09-04
AU6568200A (en) 2001-02-13
JP2003505080A (ja) 2003-02-12
AR024953A1 (es) 2002-10-30
CA2380192A1 (en) 2001-02-01
PL353733A1 (en) 2003-12-01
CN1165617C (zh) 2004-09-08
HUP0202794A3 (en) 2006-03-28
HK1048337A1 (en) 2003-03-28
HUP0202794A2 (en) 2003-03-28
NO20020365D0 (no) 2002-01-23
TR200200201T2 (tr) 2002-05-21
US6472521B1 (en) 2002-10-29
HRP20020075A2 (en) 2005-10-31
HK1048337B (zh) 2005-02-25
EP1204742A2 (de) 2002-05-15
MXPA02000817A (es) 2002-07-30
KR20020033744A (ko) 2002-05-07
SK1162002A3 (en) 2002-06-04
WO2001007602A2 (de) 2001-02-01
NZ516839A (en) 2004-04-30
DE19935303A1 (de) 2001-02-08
ZA200200655B (en) 2003-09-23

Similar Documents

Publication Publication Date Title
BR0013180A (pt) Oligonucleotìdeos para inibição da expressão de eg5 humano
MXPA04000179A (es) Oligonucleotidos sinteticos de hebra doble para inhibicion especifica de expresion de gene.
DK1076657T3 (da) Hidtil ukendte hydroxyindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling
DK0861228T3 (da) Lipopolyaminer som transfektionsmidler samt deres farmaceutiske anvendelser
NO972043D0 (no) Tienopyridin eller tienopyrimidinderivater og deres anvendelse
WO2002036743A3 (en) Antisense modulation of calreticulin expression
BR0208142A (pt) Combinações compreendendo um agente antidiarréico e epotilona ou derivado de epotilona
EP0735046A4 (en) OLIGONUCLEOTIDE AND CANCEROSTATIC AGENT THAT CONTAINS THIS AS ACTIVE INGREDIENT
WO2004007743A3 (en) Use of cpg nucleic acids in prion-disease
DK1056475T3 (da) Dendrimere fullerenderivater, fremgangsmåde til fremstilling heraf samt deres anvendelse som neuroprotektiva
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
BR0100982A (pt) Processo para a preparação de derivados deresorcinol
BR9803727A (pt) Tintas biostáveis de base em água e processo para suas preparações.
EE200000050A (et) Ravimkoostised, kasutusvalmis komplektid ja meetodid peaaju neurovaskulaarsete häirete ja lihaspingepeavalu inhibeerimiseks
BR0114379A (pt) Derivados de c-ciclohexilmetilamina substituìdos
WO2003012051A3 (en) Inhibitor of dna methylation
BR0103048A (pt) Derivados de n-triazolilmetil-piperazina como antagonistas de receptores de neuroquinina
CA2296560A1 (en) Amino acid derivatives useful to treat stroke
EP1248633A4 (en) ANTISENSE MODULATION OF GLYCOGENE SYNTHASE KINASE 3 BETA EXPRESSION
BR9811542A (pt) Identificação de linhas de células humanas para a produção de proteìnas humanas mediante ativação de genes endógena
AP2000001937A0 (en) Method for identifying chemical active agents and active agents for inhibiting the 1-desoxy-d-xylulose-5-phosphate biosynthetic pathway.
BG106748A (en) Method and compositions for treating pulmonary diseases
ITRM20000556A0 (it) S-adenosilmetionina e suoi derivati per il trattamento e la prevenzione della malattia di alzheimer.
TW200626722A (en) 11 &bgr'-HSDI antisense compounds
BR0007183A (pt) Isonipectoamidas para o tratamento de distúrbios mediados por integrina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A, 8A E 9A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.